Atazanavir Viatris: Uses, Dosage & Side Effects
An HIV protease inhibitor used in combination antiretroviral therapy to control HIV-1 infection and strengthen the immune system
Atazanavir Viatris is an antiretroviral medicine containing the active ingredient atazanavir, an HIV protease inhibitor. It is used in combination with other antiretroviral drugs, including a pharmacokinetic booster (ritonavir), to treat HIV-1 infection in adults and children aged 6 years and older. Atazanavir works by blocking an enzyme (HIV protease) that the virus needs to replicate, thereby reducing the amount of HIV in the blood and allowing the immune system to recover. It is available as hard capsules in three strengths (150 mg, 200 mg, and 300 mg) and is taken once daily with food. Atazanavir Viatris is a generic version of the original branded product REYATAZ.
Quick Facts: Atazanavir Viatris
Key Takeaways
- Atazanavir Viatris is an HIV protease inhibitor taken once daily with food, always combined with ritonavir (100 mg) and other antiretroviral medicines.
- It does not cure HIV but controls viral replication, reduces viral load, and allows the immune system to strengthen over time.
- Jaundice (yellowing of skin or eyes) is common and usually harmless, caused by elevated bilirubin levels — not liver damage.
- Numerous drug interactions exist — always tell your doctor about all medications you are taking, including supplements and over-the-counter products.
- Must be taken consistently with food to ensure adequate absorption. Missing doses can lead to drug resistance.
What Is Atazanavir Viatris and What Is It Used For?
Atazanavir Viatris contains the active substance atazanavir, which belongs to a group of medicines known as protease inhibitors. These drugs work by blocking a specific protein (HIV-1 protease) that the human immunodeficiency virus (HIV) needs in order to make copies of itself and produce new, mature virus particles. By inhibiting this enzyme, atazanavir prevents the virus from assembling functional copies, which in turn reduces the amount of HIV circulating in the bloodstream. This reduction in viral load allows the immune system, specifically CD4+ T lymphocytes, to recover and strengthen over time.
It is important to understand that atazanavir does not cure HIV infection or AIDS. Patients receiving atazanavir may still develop infections or other conditions associated with HIV disease. However, effective antiretroviral therapy significantly reduces the risk of disease progression, extends life expectancy, and can reduce the viral load to undetectable levels, which in turn lowers the risk of transmitting the virus to others. The concept of "undetectable equals untransmittable" (U=U) has become a cornerstone of modern HIV management and reflects the effectiveness of drugs like atazanavir when taken consistently as part of a combination regimen.
Atazanavir Viatris is prescribed as part of a combination antiretroviral therapy (cART) regimen. It is never used alone because monotherapy leads to rapid development of drug resistance. The standard recommended use involves taking atazanavir together with a low dose of ritonavir (a pharmacokinetic booster that increases atazanavir blood levels) and at least two other antiretroviral agents, typically nucleoside reverse transcriptase inhibitors (NRTIs). Your doctor will determine the best combination of drugs based on your individual circumstances, treatment history, resistance testing, and potential drug interactions.
Atazanavir Viatris is a generic version of the original branded product REYATAZ, manufactured by Viatris Limited (formerly Mylan). It contains the same active ingredient in the same doses and has been approved by regulatory authorities (including the European Medicines Agency) as bioequivalent to the original product. Other generic versions include Atazanavir STADA. Generics provide the same clinical efficacy and safety profile at a reduced cost, which is particularly important for global HIV treatment access.
Who Can Use Atazanavir Viatris?
Atazanavir Viatris capsules can be used by adults and children from 6 years of age and older who weigh at least 15 kg. For younger children (from 3 months of age weighing at least 5 kg), other pharmaceutical forms of atazanavir (such as oral powder) may be available. The capsule formulation is preferred once a child is able to reliably swallow capsules. Atazanavir should not be used in children younger than 3 months or weighing less than 5 kg due to the risk of serious complications, including the potential for severe hyperbilirubinemia (dangerously elevated bilirubin levels) in neonates.
What Should You Know Before Taking Atazanavir Viatris?
Contraindications
Atazanavir Viatris must not be taken in the following situations. If any of these apply, inform your doctor immediately:
- Allergy — If you are allergic (hypersensitive) to atazanavir or any of the other ingredients in the capsules (including lactose monohydrate, crospovidone, magnesium stearate, and the capsule shell components).
- Moderate to severe liver disease — Your doctor must assess the severity of any liver condition before prescribing this medicine.
- Certain medications — Atazanavir has absolute contraindications with several drugs due to the risk of life-threatening interactions (see the Drug Interactions section below for the full list).
- Rifampicin (antibiotic for tuberculosis)
- Astemizole or terfenadine (antihistamines)
- Cisapride (for gastroesophageal reflux)
- Pimozide (antipsychotic)
- Quinidine or bepridil (cardiac antiarrhythmics)
- Ergotamine, dihydroergotamine, ergonovine, methylergonovine (ergot alkaloids for migraine)
- Alfuzosin (for benign prostatic hyperplasia)
- Quetiapine, lurasidone (antipsychotics)
- St. John’s wort (Hypericum perforatum)
- Triazolam and oral midazolam (benzodiazepines)
- Lomitapide, simvastatin, lovastatin (lipid-lowering agents)
- Grazoprevir-containing products, including elbasvir/grazoprevir and glecaprevir/pibrentasvir (hepatitis C antivirals)
- Apalutamide (prostate cancer treatment)
- Encorafenib, ivosidenib (anticancer agents)
- Carbamazepine, phenobarbital, phenytoin (anticonvulsants)
- Sildenafil when used for pulmonary arterial hypertension (not when used for erectile dysfunction at adjusted doses)
Warnings and Precautions
Talk to your doctor or pharmacist before taking Atazanavir Viatris and make sure your doctor is aware of the following conditions:
- Hepatitis B or C — Patients with chronic hepatitis B or C co-infection may experience worsening of liver function during treatment. Your doctor will monitor your liver enzymes regularly.
- Gallstones — Atazanavir may increase the risk of gallbladder problems. Seek medical attention if you develop pain in the right side of your abdomen, nausea, vomiting, or fever.
- Hemophilia A or B — There have been reports of increased bleeding in patients with hemophilia taking protease inhibitors.
- Kidney disease or hemodialysis — Atazanavir may affect kidney function. Kidney stones (nephrolithiasis) have been reported. Seek immediate medical attention if you notice flank pain, blood in the urine, or pain during urination.
- Hyperbilirubinemia (jaundice) — Elevated bilirubin levels causing yellowing of the skin or eyes occur frequently with atazanavir. While generally not dangerous in adults and children older than 3 months, you should discuss this with your doctor. In rare cases, it may indicate a more serious underlying problem.
- Heart rhythm changes — Atazanavir can cause PR interval prolongation on ECG. If you experience palpitations, dizziness, or fainting, contact your doctor immediately. Children on atazanavir may need cardiac monitoring.
- Severe skin reactions — Stevens-Johnson syndrome and other serious skin rashes have been reported. Seek immediate medical attention if you develop a widespread rash, especially if accompanied by fever, blisters, or mouth sores.
In patients with advanced HIV infection who have previously had opportunistic infections, signs and symptoms of inflammation from those past infections may appear shortly after starting antiretroviral therapy. This is believed to be caused by the recovering immune system mounting a response against pre-existing infections. Additionally, autoimmune disorders (such as Graves' disease or autoimmune hepatitis) may occur weeks to months after treatment initiation. If you notice any new symptoms — including muscle weakness starting in the hands and feet, palpitations, tremor, or signs of infection — inform your doctor immediately.
Some patients on combination antiretroviral therapy develop osteonecrosis (bone death due to loss of blood supply to the bone). Risk factors include prolonged antiretroviral therapy, corticosteroid use, alcohol consumption, severe immunosuppression, and higher body mass index (BMI). Symptoms include joint stiffness and pain (especially in the hip, knee, and shoulder) and difficulty moving. Contact your doctor if you experience these symptoms.
Pregnancy and Breastfeeding
If you are pregnant, think you may be pregnant, or are planning to have a baby, talk to your doctor before taking this medicine. Your doctor will carefully weigh the potential benefits and risks of using atazanavir during pregnancy. Atazanavir, the active substance, is excreted in breast milk. Patients should not breastfeed while taking Atazanavir Viatris. Moreover, breastfeeding is not recommended for women living with HIV because the virus can be transmitted to the infant through breast milk, regardless of whether the mother is on antiretroviral therapy.
Driving and Operating Machinery
Do not drive or operate machinery if you feel dizzy or lightheaded, and contact your doctor immediately. Dizziness has been reported as an uncommon side effect of atazanavir treatment.
Lactose Content
Atazanavir Viatris capsules contain lactose monohydrate. If you have been told by your doctor that you have an intolerance to certain sugars, consult your doctor before taking this medicine.
How Does Atazanavir Viatris Interact with Other Drugs?
Atazanavir is primarily metabolized by the cytochrome P450 enzyme CYP3A4 and is also a potent inhibitor of CYP3A4, UGT1A1, and the drug transporter OATP1B1. When combined with ritonavir (a potent CYP3A4 inhibitor), the interaction potential is further amplified. This means that atazanavir can significantly increase or decrease the blood levels of many other drugs, and conversely, many drugs can alter atazanavir levels. The consequences can range from loss of antiviral efficacy (if atazanavir levels drop too low) to dangerous toxicity (if co-administered drug levels rise too high).
Always tell your doctor or pharmacist about all medicines you are taking, have recently taken, or plan to take — including prescription drugs, over-the-counter products, herbal remedies, and dietary supplements. The following tables summarize the most important interactions.
Major Interactions (Contraindicated)
The drugs listed below must never be taken together with Atazanavir Viatris due to the risk of serious or life-threatening adverse effects:
| Drug / Class | Reason for Contraindication |
|---|---|
| Rifampicin | Dramatically reduces atazanavir levels, leading to treatment failure and resistance |
| Ergot alkaloids (ergotamine, dihydroergotamine, ergonovine, methylergonovine) | Risk of acute ergot toxicity including vasospasm and limb ischemia |
| Pimozide, quetiapine, lurasidone | Risk of serious cardiac arrhythmias (QT prolongation) and excessive sedation |
| Simvastatin, lovastatin, lomitapide | Risk of severe myopathy and rhabdomyolysis due to greatly increased statin levels |
| Oral midazolam, triazolam | Risk of prolonged or excessive sedation and respiratory depression |
| St. John’s wort (Hypericum perforatum) | Reduces atazanavir levels by inducing CYP3A4, risking treatment failure |
| Carbamazepine, phenobarbital, phenytoin | Potent CYP3A4 inducers that substantially reduce atazanavir plasma levels |
| Sildenafil (for pulmonary hypertension) | Risk of severe hypotension and other sildenafil-related adverse effects |
| Grazoprevir-containing products (elbasvir/grazoprevir, glecaprevir/pibrentasvir) | Risk of elevated ALT (liver enzymes) and increased grazoprevir exposure |
Important Interactions Requiring Dose Adjustment or Monitoring
The following drug interactions require careful management. Your doctor may need to adjust doses, alter timing of administration, or monitor you more closely:
| Drug / Class | Management |
|---|---|
| Antacids | Take antacids at least 1 hour before or 2 hours after atazanavir |
| H2-receptor antagonists (e.g., famotidine) | Dose separation required; do not exceed specific H2 blocker doses |
| Proton pump inhibitors (e.g., omeprazole) | Generally not recommended with boosted atazanavir; significant reduction in drug levels |
| Efavirenz, nevirapine | Can reduce atazanavir levels; dose adjustments may be needed |
| Atorvastatin, pravastatin, fluvastatin | Use lowest possible statin dose with monitoring for muscle toxicity |
| Sildenafil, vardenafil, tadalafil (for erectile dysfunction) | Use reduced doses with increased monitoring for side effects |
| Hormonal contraceptives | Take exactly as instructed by your doctor; atazanavir may alter hormone levels |
| Amiodarone, diltiazem, verapamil, lidocaine (systemic) | ECG monitoring advised; risk of additive PR prolongation or cardiac effects |
| Cyclosporine, tacrolimus, sirolimus | Blood level monitoring of immunosuppressant required; dose reduction likely needed |
| Rifabutin | Reduce rifabutin dose to 150 mg every other day or three times per week |
| Warfarin, apixaban, rivaroxaban, dabigatran, edoxaban | Monitor anticoagulation closely; dose adjustments may be needed |
| Salmeterol | Combination not recommended; risk of cardiovascular adverse effects |
| Inhaled/nasal corticosteroids (fluticasone, budesonide) | Risk of Cushing syndrome and adrenal suppression when combined with ritonavir; consider alternatives |
| Buprenorphine | Monitor for sedation and cognitive effects; dose reduction may be needed |
| Lamotrigine | Atazanavir/ritonavir may reduce lamotrigine levels; monitor anticonvulsant efficacy |
Atazanavir requires an acidic stomach environment for proper absorption. Medications that raise gastric pH — including antacids, H2 blockers, and proton pump inhibitors — can significantly reduce atazanavir blood levels, potentially leading to treatment failure and development of drug resistance. If you need these medications, discuss timing and dosing strategies with your doctor. In general, proton pump inhibitors should be avoided if possible when taking boosted atazanavir.
What Is the Correct Dosage of Atazanavir Viatris?
Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure. By taking the medicine correctly, you ensure full efficacy and reduce the risk of the virus developing resistance to the treatment. Adherence to antiretroviral therapy is critically important — even occasional missed doses can allow the virus to replicate and potentially develop mutations that make the drug less effective.
Adults
Standard Adult Dose
Atazanavir 300 mg (one 300 mg capsule or two 150 mg capsules) taken once daily together with ritonavir 100 mg once daily, with food, in combination with other antiretroviral medicines.
Your doctor may adjust the dose depending on the other antiretroviral medicines in your regimen. In some specific treatment-naive scenarios, atazanavir 400 mg once daily without ritonavir boosting may be considered, but boosted therapy (with ritonavir) is generally preferred for more reliable drug levels.
Children (6 to <18 Years)
The dose for children is determined by body weight. Atazanavir Viatris capsules are taken once daily with food together with ritonavir 100 mg:
| Body Weight | Atazanavir Dose (once daily) | Ritonavir Dose (once daily) |
|---|---|---|
| 15 kg to <35 kg | 200 mg | 100 mg |
| 35 kg or more | 300 mg | 100 mg |
Ritonavir capsules, tablets, or oral solution may be used for the booster dose. Other pharmaceutical forms of atazanavir (such as oral powder) may be available for younger children (from 3 months of age weighing at least 5 kg). Transitioning from other formulations to capsules is encouraged as soon as the child can reliably swallow capsules. A dose change may be necessary when switching between formulations — your doctor will determine the correct dose.
There are no dose recommendations for atazanavir in children younger than 3 months.
How to Take the Capsules
- Take Atazanavir Viatris capsules with food (a meal or a substantial snack) to ensure adequate absorption.
- Swallow the capsules whole. Do not open, crush, or chew them.
- Take the medicine at approximately the same time each day to maintain consistent blood levels.
Missed Dose
If you forget to take a dose, take it as soon as you remember together with food, then take your next dose at the regular scheduled time. If it is almost time for your next dose, skip the missed dose and continue with your normal schedule. Do not take a double dose to make up for a forgotten one.
Overdose
Symptoms of overdose may include yellowing of the skin and/or eyes (jaundice) and irregular heart rhythm (QTc prolongation). If you or your child accidentally takes more capsules than prescribed, contact your HIV doctor or go to the nearest emergency department immediately for advice.
Stopping Treatment
Do not stop taking Atazanavir Viatris without first talking to your doctor. Abruptly discontinuing antiretroviral therapy can cause the viral load to increase rapidly (viral rebound), which may lead to immune deterioration and increased risk of developing drug-resistant virus. If you experience side effects, discuss alternative treatment strategies with your healthcare provider rather than stopping on your own.
What Are the Side Effects of Atazanavir Viatris?
Like all medicines, Atazanavir Viatris can cause side effects, although not everybody gets them. During HIV treatment, it can be difficult to determine which side effects are caused by atazanavir specifically, which by other medicines in the regimen, and which by the HIV infection itself. Tell your doctor if you notice anything unusual about your health.
During HIV treatment, weight gain and increased levels of lipids (fat) and glucose in the blood may occur. This is partly linked to restored health and lifestyle, but for blood lipids, there may sometimes be a link to the HIV medicines themselves. Your doctor will test for such changes.
- Severe skin rash with flu-like symptoms, blisters, fever, mouth sores, muscle or joint pain, facial swelling, eye inflammation (conjunctivitis), or painful, warm, red nodules
- Dizziness or sudden fainting (may indicate heart rhythm problems)
- Dark (tea-colored) urine, intense itching, yellowing of skin/eyes, abdominal pain, pale stools, or nausea (possible liver problems)
- Pain in the lower back or lower abdomen, blood in urine, or pain during urination (possible kidney stones)
- Pain in the right or middle upper abdomen with nausea, vomiting, or fever (possible gallbladder problems)
Side Effect Frequency Guide
Common
May affect up to 1 in 10 people
- Jaundice (yellowing of skin or eyes due to elevated bilirubin)
- Headache
- Nausea and vomiting
- Diarrhea
- Abdominal pain
- Dyspepsia (indigestion)
- Extreme tiredness (fatigue)
Uncommon
May affect up to 1 in 100 people
- Peripheral neuropathy (numbness, weakness, tingling, or pain in arms and legs)
- Hypersensitivity (allergic reaction)
- Asthenia (unusual tiredness or weakness)
- Weight loss, weight gain, anorexia (loss of appetite), increased appetite
- Depression, anxiety, sleep disorders, insomnia
- Disorientation, memory loss, dizziness, somnolence (drowsiness), abnormal dreams
- Syncope (fainting), hypertension (high blood pressure)
- Dyspnea (shortness of breath)
- Pancreatitis (pancreatic inflammation), gastritis, aphthous stomatitis (mouth ulcers), dysgeusia (altered taste), flatulence, dry mouth, abdominal distension
- Angioedema (severe swelling of skin and tissues, often around lips or eyes)
- Alopecia (hair loss), pruritus (itching)
- Muscle atrophy (muscle wasting), arthralgia (joint pain), myalgia (muscle pain)
- Interstitial nephritis (kidney inflammation), hematuria (blood in urine), proteinuria (excess protein in urine), pollakiuria (frequent urination)
- Gynecomastia (breast enlargement in men)
- Chest pain, malaise, fever
- Kidney stones, gallbladder problems
- Heart rhythm changes (PR interval prolongation)
Rare
May affect up to 1 in 1,000 people
- Abnormal gait (unusual walking pattern)
- Edema (swelling)
- Hepatosplenomegaly (enlargement of liver and spleen)
- Myopathy (muscle pain and weakness not caused by exercise)
- Kidney pain
- Stevens-Johnson syndrome (severe skin reaction)
Metabolic Side Effects
Patients receiving combination antiretroviral therapy may experience metabolic changes including redistribution of body fat (lipodystrophy), elevated blood sugar levels, and changes in blood lipid profiles. These changes are common across many antiretroviral regimens and may require additional monitoring and management. Your doctor will perform regular blood tests to detect such changes. Maintaining a healthy diet and regular physical activity can help manage these metabolic effects.
Reporting Side Effects
If you experience any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed here. You can also report side effects directly to your national pharmacovigilance authority. By reporting side effects, you can help provide more information on the safety of this medicine.
How Should You Store Atazanavir Viatris?
Proper storage of antiretroviral medications is essential to maintain their effectiveness. Store Atazanavir Viatris under the following conditions:
- Temperature: Store at or below 25°C (77°F). Do not freeze.
- Packaging: Keep the capsules in their original packaging (blister pack or bottle) to protect from moisture.
- Bottles: If supplied in a bottle, use the contents within 90 days of first opening.
- Expiry date: Do not use this medicine after the expiry date shown on the label, carton, or blister pack. The expiry date refers to the last day of that month.
- Children: Keep this medicine out of the sight and reach of children.
- Disposal: Do not dispose of medicines via wastewater or household waste. Ask your pharmacist how to dispose of medicines you no longer use. These measures help to protect the environment.
What Does Atazanavir Viatris Contain?
Active Ingredient
Each capsule contains atazanavir (as sulfate) in one of three strengths:
- 150 mg capsules: Green-blue and blue opaque capsules printed with “MYLAN” over “AR150” in black ink
- 200 mg capsules: Blue and green-blue opaque capsules printed with “MYLAN” over “AR200” in black ink
- 300 mg capsules: Red and green-blue opaque capsules printed with “MYLAN” over “AR300” in black ink
Inactive Ingredients (Excipients)
The other ingredients are:
- Capsule contents: Lactose monohydrate, crospovidone, magnesium stearate
- Capsule shell: Gelatin, titanium dioxide (E171), plus strength-specific colorants:
- 150 mg: Iron oxide red (E172), patent blue V (E131)
- 200 mg: Indigotine (E132), iron oxide yellow (E172), patent blue V (E131)
- 300 mg: Iron oxide yellow (E172), iron oxide red (E172), patent blue V (E131)
- Printing ink: Shellac, propylene glycol, concentrated ammonia solution, iron oxide black (E172), potassium hydroxide
Pack Sizes
Atazanavir Viatris is available in blister packs and bottles:
- 150 mg: Blister packs of 60 or 60 × 1 (unit-dose) capsules, or bottles of 60 capsules
- 200 mg: Blister packs of 30, 60, or 60 × 1 (unit-dose) capsules, or bottles of 60 capsules
- 300 mg: Blister packs of 30 or 30 × 1 (unit-dose) capsules, or bottles of 30 or 90 capsules
Not all pack sizes may be marketed in all countries.
Marketing Authorization Holder
Viatris Limited, Damastown Industrial Park, Mulhuddart, Dublin 15, Ireland.
Frequently Asked Questions
Atazanavir Viatris is used to treat HIV-1 infection in adults and children aged 6 years and older. It belongs to the protease inhibitor class and is always used in combination with other antiretroviral medicines and a booster (ritonavir 100 mg). It reduces the amount of HIV in the blood and helps strengthen the immune system. It does not cure HIV but controls the infection when taken consistently.
Atazanavir inhibits the liver enzyme UGT1A1, which processes bilirubin. This leads to elevated unconjugated bilirubin in the blood (hyperbilirubinemia), causing a yellowish discoloration of the skin and the whites of the eyes. This side effect is generally harmless in adults and children over 3 months old and is not a sign of liver damage. It usually resolves once the medication is discontinued. However, always discuss any yellowing with your doctor to rule out other causes.
Acid-reducing medicines can significantly reduce atazanavir absorption because the drug requires an acidic stomach environment. Antacids should be taken at least 1 hour before or 2 hours after atazanavir. H2 blockers (like famotidine) require dose separation and dose limits. Proton pump inhibitors (like omeprazole) are generally not recommended with boosted atazanavir because they can reduce drug levels to subtherapeutic concentrations. Always consult your doctor before combining any acid-reducing medication with atazanavir.
If you miss a dose, take it as soon as you remember together with food. Then take the next dose at the usual time. If it is nearly time for your next scheduled dose, skip the missed dose and continue with your regular schedule. Never take a double dose. Consistent adherence is critical to prevent the virus from developing resistance to treatment.
The use of atazanavir during pregnancy should be decided by your doctor based on the benefits and risks. Atazanavir passes into breast milk. Breastfeeding is not recommended for women living with HIV, regardless of antiretroviral treatment, because HIV can be transmitted to the baby through breast milk. If you are pregnant, planning to become pregnant, or breastfeeding, discuss your options with your healthcare provider as soon as possible.
Atazanavir Viatris is a generic version of REYATAZ. Both contain the same active ingredient (atazanavir) in the same doses and have been shown to be bioequivalent — meaning they are absorbed and work in the body in the same way. The EMA and other regulatory authorities have confirmed that generics like Atazanavir Viatris provide the same efficacy and safety as the original branded product. The primary difference is the manufacturer (Viatris vs. Bristol-Myers Squibb) and typically a lower cost.
References
- European Medicines Agency (EMA). Atazanavir Viatris — Summary of Product Characteristics. Last updated 2025. Available at: www.ema.europa.eu
- U.S. Food and Drug Administration (FDA). REYATAZ (atazanavir) — Prescribing Information. Revised 2024. Available at: www.accessdata.fda.gov
- Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. Department of Health and Human Services (DHHS). Updated 2025. Available at: clinicalinfo.hiv.gov
- European AIDS Clinical Society (EACS). EACS Guidelines Version 12.0, 2024. Available at: www.eacsociety.org
- World Health Organization (WHO). Consolidated Guidelines on HIV Prevention, Testing, Treatment, Service Delivery and Monitoring. Geneva: WHO; 2024. Available at: www.who.int
- Molina JM, et al. Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE study. J Acquir Immune Defic Syndr. 2010;53(3):323-332.
- Malan DR, et al. Efficacy and safety of atazanavir, with or without ritonavir, as part of once-daily highly active antiretroviral therapy regimens in antiretroviral-naive patients. J Acquir Immune Defic Syndr. 2008;47(2):161-167.
- British National Formulary (BNF). Atazanavir monograph. Available at: bnf.nice.org.uk
Medical Editorial Team
Medical Content
iMedic Medical Editorial Team — Specialists in infectious diseases and clinical pharmacology
Medical Review
iMedic Medical Review Board — Independent panel of medical experts reviewing according to international guidelines (WHO, DHHS, EACS, EMA)
Evidence Framework
GRADE evidence framework — All medical claims based on Level 1A evidence from systematic reviews and randomized controlled trials
Independence
No pharmaceutical company sponsorship — All content is editorially independent with no commercial funding or conflicts of interest
Last medically reviewed: . Content is updated regularly to reflect the latest clinical evidence and regulatory guidance.